Does Mounjaro Increase Fertility — and What Should You Know Before Trying to Conceive?

The misconception that needs to go first

A claim circulates (particularly on social media) that Mounjaro is a fertility treatment in its own right, or that tirzepatide directly stimulates ovulation or improves sperm quality. It is easy to see where this comes from. People who have struggled to conceive for years sometimes begin losing weight on Mounjaro, their cycles regularise, and a pregnancy follows. That sequence is real. The mechanism, though, is indirect: the weight loss is doing the work, not the drug acting on reproductive tissue. Mounjaro has no licensed indication for infertility, and no clinical trial has been designed to measure it as a primary outcome.

Letting that misconception go gently matters, because it shapes how you plan. If you start tirzepatide hoping it will function as a fertility drug, you may be disappointed, and you may also be weighing up risks (particularly around stopping the medicine before conception) without the full picture. The picture is more nuanced, and genuinely more hopeful in some respects, than the simplified version suggests.

For background on how the medicine works and what it is licensed for, the Mounjaro overview on our site covers the clinical detail.

How weight loss through tirzepatide can affect reproductive health

Excess weight disrupts the hormonal signals that regulate ovulation. In polycystic ovary syndrome specifically, raised insulin levels contribute to androgen excess, which suppresses normal follicle development. Because Mounjaro reduces appetite and promotes significant weight loss, insulin sensitivity often improves, androgen levels can fall, and for some women ovulation resumes or becomes more regular. This is the same mechanism that makes lifestyle weight loss effective in PCOS, the medicine is accelerating that process, not bypassing it.

The NHS medicines page for tirzepatide confirms that irregular periods are listed among the side effects and changes some people notice, consistent with hormonal shifts during treatment. There is emerging observational data suggesting fertility can return more quickly than expected during tirzepatide treatment, which is why the contraception guidance is as explicit as it is.

For people curious about how dose progression relates to the degree of weight loss, our page on whether increasing the Mounjaro dose increases weight loss covers the trial evidence in depth.

The stop-before-conceiving guidance, and why contraception matters sooner than you might think

The MHRA and NHS England's guidance on weight-management injections are consistent: Mounjaro should not be used during pregnancy. Animal data have shown developmental effects at doses relevant to human treatment, and because the medicine's effects on a human embryo are not fully established, caution is the only responsible position. The practical consequence is that you should stop Mounjaro and allow time before trying to conceive, your prescriber or GP will advise on the appropriate wash-out interval based on your specific circumstances.

The contraception piece is its own important chapter. Because Mounjaro slows gastric emptying, the absorption of oral contraceptive pills can be reduced, particularly in the early weeks of treatment and after dose increases. If you want to understand how Mounjaro dose increases work and what they involve, that context makes the contraception guidance easier to follow in practice. The MHRA guidance, echoed by NHS Scotland, is to use a non-oral method (condoms, for example) alongside the pill for the first four weeks of starting Mounjaro and for four weeks after any dose increase. This is not a warning to stop the pill; it is a practical instruction to add a second method during a defined window. Missing this step is exactly how unplanned pregnancies on tirzepatide occur.

If you are thinking about whether to change dose timing around family planning, our guide on when to increase your Mounjaro dose may help frame that conversation with your prescriber, and our page covering why increasing the Mounjaro dose is recommended at certain points adds useful context to that decision.

Who to talk to, and what that conversation should cover

This is a situation where a single trusted clinician who holds the full picture is worth considerably more than a search result. Your GP can review your reproductive history, refer to a gynaecologist or fertility specialist if that is appropriate, and advise on timing if you are considering stopping treatment before trying to conceive. If you are mid-treatment and your cycle has changed noticeably, that too is worth flagging, both as a sign the medicine may be working metabolically and as a reason to revisit your contraception.

Our prescribers at nume can discuss Mounjaro treatment, dose management, and the contraception guidance in detail. What they cannot replace is specialist fertility input if that is what your situation calls for. These conversations work best in parallel, not in sequence. If you have not yet started treatment and want to understand your options, checking your eligibility through a free consultation is the place to begin, a real prescriber, not an automated system, will review your full picture the same day.

For questions about what treatment costs and what is included in a private consultation, our Mounjaro pricing page sets that out clearly.